K. Young

Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.

G. O’Kane, N. Leighl, M. Doherty, 2017, The oncologist.

The impact of beta blockers on survival outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors

A. Behdad, D. Wainwright, V. Villaflor, 2021 .

Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients.

F. Shepherd, Geoffrey Liu, S. Keshavjee, 2020, Lung cancer.

Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population‐based reflex testing

M. Tsao, C. Cheung, G. da Cunha Santos, 2019, Cancer.

The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective

G. da Cunha Santos, N. Leighl, P. Card, 2018, Cancer cytopathology.

Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis.

R. Kurek, F. Shepherd, L. Paz-Ares, 2018, Thrombosis research.